FDA approves ReNeuron’s IND application to commence a Phase IIb clinical trial in the US in stroke disability
14 December 2017: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, is pleased to announce that the FDA has given regulatory approval for the Company to commence a Phase IIb clinical study in the US with its CTX cell therapy candidate for stroke disability.